drugset / Trial / NCT04898309
Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema
RandomizedParallel-groupDouble-blindTreatment
Summary
It is a placebo-controlled randomized trial to evaluate the efficacy and safety of GNR-038 in comparison with Berinert® in patients with hereditary angioedema
Timeline
- Start
- 2021-12-01
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CINRYZE | Protein / enzyme biologic | 20 iu/kg | Intravenous |
| Subject | GNR-038 | Protein / enzyme biologic | 50 iu/kg | Intravenous |
| Subject | GNR-038 | Protein / enzyme biologic | 100 iu/kg | Intravenous |